Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Amniotic epithelial stem cells (AESCs), also known as human amniotic epithelial cells (hAECs), are pluripotent-like cells derived from the innermost layer of the human term placenta. These cells are characterized by their low immunogenicity, lack of tumorigenicity, and potent immunomodulatory properties. In clinical applications, such as the treatment of ocular chronic graft-versus-host disease (cGVHD), AESCs are formulated into eye drops to provide a localized therapeutic effect. They function by modulating the inflammatory environment of the ocular surface and promoting the repair of damaged corneal tissues, offering a potential alternative to conventional immunosuppressive treatments for patients suffering from debilitating ocular symptoms following hematopoietic stem cell transplantation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on amniotic epithelial stem cell.